Showing 2637 results
- Media Library /
- Media Release /Phase II study efficacy data showed overall response rate of 72.0% and 39.1%, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping mutated non-small…
- Media Release /Lutathera treatment was associated with an ~80% reduction in the estimated risk of tumor progression or death vs comparator, regardless of baseline liver tumor burden[1] Lutathera treatment was…
- Media Release /Phase III PSMAfore trial with Pluvicto™ met its primary endpoint of radiographic progression-free survival (rPFS) with a HR of 0.411; Pluvicto more than doubled median rPFS to 12.0 months per updated…
- Key Release /Novartis to acquire Endocyte to accelerate development of innovative radioligand technology for treating cancer Acquisition would add 177Lu-PSMA-617, a potential first-in-class…
- Key Release /Net sales grew 6% (cc[1], +3% USD) mainly driven by: Cosentyx grew to USD 750 million (+37% cc) with strong volume growth across indications Entresto more than doubled to USD 271 million (+113…
- Media Release /OPTIMA Phase IIIb data re-confirm that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled[1] Should a treatment pause be necessary, data showed almost…
- Media Release /51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira®* safety and efficacy profile[1]Sandoz proposed biosimilar adalimumab is currently under…
- Media Release /Cosentyx® (secukinumab) is the first and only fully human IL-17A inhibitor to show sustained skin clearance rates at 5 years in phase III in psoriasis[1] Landmark data show that PASI…
- Media Release /Rituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis[1] Sandoz believes the comprehensive data package submitted to the FDA for review confirms…
Pagination
- ‹ Previous page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- …
- 264
- › Next page